IPP Bureau
BDR Pharma launches enzalutamide in 160 mg strength
By IPP Bureau - February 28, 2022
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
First oral diabetes treatment approved in Europe for use during pregnancy
By IPP Bureau - February 28, 2022
In a European work-sharing procedure (WSP), Glucophage was approved as the first oral anti-diabetic medication to be used safely from conception to birth
Researchers develop a fast, efficient tech to remove pollutants from water
By IPP Bureau - February 28, 2022
The method shows the removal of seven types of PFAS – even when all of them are found in the same unit of fluid – at a level of efficiency that approaches 90%, and it does so within a few minutes
Mankind Pharma completes acquisition of Panacea Biotec’s domestic business for Rs 1872 cr
By IPP Bureau - February 28, 2022
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
Jeffrey DeAlmeida appointed Senior VP of BASF pharma solutions
By IPP Bureau - February 28, 2022
In this role, Jeffrey DeAlmeida takes responsibility for BASF’s global pharmaceutical solutions portfolio and the Nutrition & Health business in North and South America
Prenetics Partners and ACON Bio launch Covid-19 antigen kits
By IPP Bureau - February 27, 2022
Flowflex antigen test detects Covid-19, including the Omicron variant, in just 15 minutes with 98.8% accuracy
Cabinet approves Ayushman Bharat Digital Mission at an outlay of Rs 1,600 cr.
By IPP Bureau - February 27, 2022
Citizens will be able to create their ABHA (Ayushman Bharat Health Account) numbers, to which their digital health records can be linked
New data reinforces efficacy of Tezspire
By IPP Bureau - February 27, 2022
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
DiscGenics presents positive Phase1/2 study of Cell therapy for degenerative disc disease
By IPP Bureau - February 27, 2022
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
Oxford BioDynamics launches its Checkpoint Inhibitor response test in the US
By IPP Bureau - February 27, 2022
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
VBI’s 3-antigen Hepatitis B vaccine gets CHMP nod
By IPP Bureau - February 27, 2022
If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.
LivaNova announces first patient implanted in OSPREY clinical study
By IPP Bureau - February 27, 2022
Study to evaluate effectiveness of hypoglossal nerve stimulation
Alps Pharma launches a new water soluble Isoquercetin
By IPP Bureau - February 27, 2022
Eubio Isoquercetin derived from Sophora Japonica is expected to deliver more Quercetin to the body via small doses of Isoquercetin.
Daewoong completes combination therapy of antidiabetic drug Enavogliflozin
By IPP Bureau - February 27, 2022
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
HitGen completes research collaboration with MTPC
By IPP Bureau - February 27, 2022
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
